Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05137665 · ClinicalTrials.gov registry record
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
A clinical trial of Amyotrophic Lateral Sclerosis and Movement Disorders, sponsored by Target ALS Foundation.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 12
- Study locations
NCT05137665: Recruiting study of Amyotrophic Lateral Sclerosis and Movement Disorders, sponsored by Target ALS Foundation.
NCT05137665 is a study of Amyotrophic Lateral Sclerosis and Movement Disorders that is actively recruiting participants, run by Target ALS Foundation. The registered enrollment target is 1,000 participants, above the 888-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (13% higher). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05137665, a study of Amyotrophic Lateral Sclerosis and Movement Disorders, is actively recruiting participants, sponsored by Target ALS Foundation.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 12
- Study locations
Study Summary
The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants. ALS participants will be asked to come to the clinic for 5 study visits approximately every 4 months. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.
Primary Outcome
This project will create a biorepository of longitudinal biofluid samples, linked to clinical measures, and at home measures
Conditions Studied
Study Locations (12)
Other
- Instituto Roosevelt - Bogotá
- CHALS-CCT UPR MScience - San Juan
Arizona
- Barrow Neurological Institute - Phoenix
California
- University of California San Diego - San Diego
District of Columbia
- Georgetown University - Georgetown
Florida
- Mayo Clinic - Jacksonville
Illinois
- Northwestern University - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2031-12-31 |
What NCT05137665 shows while recruiting
NCT05137665 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 888-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (13% higher).
The record links to 4 conditions, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT05137665 lists 12 locations in 11 states (Other, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT05137665 about?
NCT05137665 is a clinical study titled "Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures". The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amy...
What is the current status of trial NCT05137665?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-06-01. Estimated completion is 2031-12-31.
What conditions does trial NCT05137665 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis, Movement Disorders, Motor Neuron Disease, Degenerative Disorder.
Who is sponsoring clinical trial NCT05137665?
This trial is sponsored by Target ALS Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05137665 being conducted?
This trial has 12 study locations across Arizona, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05137665's enrollment target sits among peer trials
1,000 12th of 102 higher than 90 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
RECRUITING · NA
-
Assessing Perceptual Effects of Interactive Tasks
RECRUITING · NA
-
PREVENT ALL ALS Study
RECRUITING
-
Spinal Cord Associative Plasticity for ALS
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI